Emerging evidence suggests a link between gut microbiota, bile acid metabolism, and immune dysregulation in dyslipidemia. Through a case-control study involving 140 participants and animal experiment, we identified significantly elevated count of peripheral blood CD3+ T cells, CD4+ T cells, CD8+ ...
Dyslipidemia is a major cardiovascular risk factor. While dietary phytosterols are known to lower cholesterol, the mechanisms involving the gut-liver axis are not fully understood. By integrating human clinical trials and mechanistic animal models, we demonstrate that phytosterols improve lipid p...
To test whether NDGA attenuate dyslipidemia and hepatic steatosis by enhancing fatty acid oxidation through activation of PPAR-α. Using wild type (WT, C57BL/6) fed with chow diet as control, WT mice were either fed with high-fat diet or high-fat diet with NDGA (2.5g/kg food); ob/ob mice were fed wit...
Dyslipidemia and inflammation play key roles in the pathogenesis of both nonalcoholic fatty liver disease (NAFLD) and atherosclerosis. NAFLD, particularly its severe form nonalcoholic steatohepatitis (NASH) is associated with increased cardiovascular disease (CVD) risk. HDL (high density lipoprotein...
